MMMaryam Mohammadi

Maryam Mohammadi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Maryam Mohammadi has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    An Integrative In Silico Mathematical Modelling Study of The Anti-Cancer Effect of Clove Extract (Syzygium aromaticum) Combined with In Vitro Metabolomics Study Using 1HNMR Spectroscopy

    by Mehri Azadi, Fatemeh Alemi, Sedigheh Sadeghi, Maryam Mohammadi, Nowrooz Ali Rahimi, Sako Mirzaie, Farideh Vahabi, Shirin Parvaz, Mohammad Arjmand, Zahra Zamani

    Clove oil is known for its medicinal properties. The mechanism of anti-cancer properties of Syzygium aromaticum were investigated by mathematical modelling on the genome scale with metabolomics using 1H Nuclear Magnetic Resonance spectroscopy on Raji cells. An integrative analysis correlated the metabolites identified by 1HNMR and genes with the detected pathways. Raji cells treated with clove oil were collected and sent for 1HNMR spectroscopy and the spectra analyzed by MATLAB and Human Metabolome Database for metabolite identification. Pathway and topology analysis was implemented using the genes and metabolites in the integrative analysis of Metaboanalyst software. 50% inhibitory concentration of clove oil was 50 µg/ml and the model anticipated 74 genes with differentiating metabolites being some amino acids, cholesterol and fucose. The integrative study predicted that the anti cancer mechanism of clove oil involves novel enzymes, as likely drug targets, 24-dehydrocholesterol reductase and 7-dehydrocholesterol reductase in cholesterol biosynthesis, dehydrofolate reductase in one carbon metabolism and serine palmitoyl-transferase long chain in sphingolipid biosynthesis.


  • Open Access

    A Study of Synergy of Combination of Eosin B with Chloroquine, Artemisinin, and Sulphadoxine-Pyrimethamine on Plasmodium falciparum In Vitro and Plasmodium berghei In Vivo

    by Sedigheh Sadeghi, Zarrintaj Valadkhani, Alireza Sadeghi Tafreshi, Mohammad Arjmand, Hossein Nahravanian, Farideh Vahabi, Neda Soori, Maryam Mohammadi, Masoomeh Meigooni, Zahra Zamani

    Background and Objectives. Artemisinin is the popular antimalarial medication, but it has to be used in combination with other drugs as its monotherapy causes resistance. The effectiveness of eosin B, a laboratory stain, as a competent antimalarial agent was identified earlier. It was tested in combination with different antimalarial drugs such as artesunate (a derivative of artemisinin) or chloroquine or sulphadoxine-pyrimethamine in vitro on Plasmodium falciparum and in vivo on Plasmodium berghei using Peter’s suppression test. Methods. Drug assessment was carried out singly or in combination on Plasmodium falciparum in vitro using the candle jar method at three inhibitory concentrations. Percent parasitemia of live cells was obtained by microscopic counting. Peter’s suppression test was carried out on mice infected with Plasmodium berghei after 3 administration of the drugs singly and in combination, and parasites were counted by microscopy for 10 days. Results. Synergy was exhibited by isobolograms of eosin B combined with artesunate and sulphadoxine-pyrimethamine with more than 10 fold reduction of all drugs in vitro. A good combination index was obtained with artesunate at 50% inibitory concentration with 3.4 nM eosin B and 1.7 nM artesunate in contrast to 124 nM eosin B and 7.6 nM artesunate singly. In vivo studies also showed a considerable lowering of the effective dose of eosin B 30 mg/kg: artesunate 3 mg/kg with 200 mg/kg eosin B and 60 mg/kg artesunate separately. Sulphadoxine-pyrimethamine seemed to have the greatest synergistic effect with a combination index of 0.007, but this could be due to it consisting of a combination of three drugs. Eosin B’s combination index with chloroquine was fair, and in vivo tests too did not show as much competence as the other two drugs. Conclusion and Interpretation. It can be concluded that eosin B can be used in combination with antimalarial drugs with favorable results.